Mounjaro®
Starting from £179.99/mo
Start journey Learn moreShortness of breath is not listed as a common or expected side effect of semaglutide in the UK licensed prescribing information. If you notice breathlessness while taking Wegovy, the cause is worth tracing carefully — it is rarely the medicine itself, and dismissing it just as a side effect carries its own risk. This page works through what the evidence actually shows, when breathlessness does and does not point toward semaglutide, and what to do if you're concerned. Semaglutide (Wegovy) is a prescription-only medicine; any symptom questions specific to your situation are best raised with a prescriber.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A fair number of people starting Wegovy search for "shortness of breath" after noticing they feel slightly different in the first weeks of treatment. The assumption (understandable, given how actively the internet catalogues GLP-1 side effects) is that the medicine must be responsible. The UK prescribing information for semaglutide 2.4 mg, reviewed by the NHS medicines team, does not include shortness of breath in its common adverse effect profile. The effects that do appear consistently are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and related discomfort. These typically surface after starting treatment or after each dose step, then settle for most people within a couple of weeks.
That absence from the list is meaningful. It comes from clinical trials involving thousands of adults over 68 weeks, with close adverse-event monitoring. Breathlessness at a frequency worth including would have appeared. So the first fact to hold onto is: if you're breathing less comfortably on semaglutide, looking for the cause elsewhere is the right instinct, not an excuse to ignore it.
There is one narrow exception worth noting. Severe, prolonged nausea and vomiting (a genuine experience for some people at dose increases) can lead to dehydration and, in susceptible individuals, electrolyte disturbance. Shallow or slightly laboured breathing can accompany significant dehydration. If breathlessness follows a bad patch of sickness, hydration is the first thing to address and a clinician should know about it. A quick check: if you can't keep fluids down for more than 24 hours, that warrants a call to your GP or the aftercare team, not a wait for the next appointment.
This is where the picture gets more interesting. Semaglutide does not act directly on the lungs or airways. But significant weight loss (often 5–10 % of body weight in the first months of treatment) reshapes the body in ways that affect respiratory mechanics. Fat tissue around the chest wall and diaphragm reduces; abdominal pressure on the diaphragm eases. Most people find breathing becomes easier over time, not harder.
However, the transition is not always smooth. People with obstructive sleep apnoea, for example, may notice their breathing pattern shifts noticeably as weight comes off, sometimes feeling unusual during the day before the condition fully resolves. People with underlying heart failure or pulmonary hypertension may experience symptom fluctuation as haemodynamics change with weight. None of this is the medicine causing breathlessness; it is weight loss interacting with pre-existing physiology.
If you've been exploring how semaglutide produces weight loss, it's worth understanding that the appetite and metabolic changes are substantial, the body adjusts, and for some conditions that adjustment period surfaces symptoms that deserve monitoring rather than panic. The key question is always: is the breathlessness new, worsening, or accompanied by other symptoms like chest tightness or leg swelling? If yes, see a clinician the same day.
None of the above should encourage anyone to normalise breathlessness and carry on. Shortness of breath is a symptom the body uses to signal several serious conditions, and being on a weight-management medicine does not change that calculus.
Seek same-day medical help if breathlessness comes on suddenly or is severe, if it's accompanied by chest pain or pressure, palpitations, a rapid or irregular heartbeat, swollen ankles or legs, or if you feel faint. These patterns (whatever else might be going on) need assessment for cardiac or pulmonary causes. The MHRA Yellow Card scheme exists precisely so that unexpected symptoms during any medicine treatment are logged and reviewed at a population level; reporting is open to patients and does not require a formal diagnosis.
There is also a separate signal worth knowing. Some people experience breathlessness as part of a severe allergic reaction to semaglutide, rare, but possible. Swelling of the face, throat, lips or tongue alongside breathing difficulty is an emergency. Call 999. This is distinct from the gradual, mild sensation of being slightly more breathless during exertion that some people describe early in treatment. People sometimes also notice other unexpected oral symptoms at this stage, and if you're wondering whether Wegovy can cause bad breath, that question is covered separately and is worth a look alongside any other early side effects you're tracking.
If your breathlessness is mild, exertion-related, and you're also navigating questions about nutrition while on Wegovy, it's worth considering whether low calorie intake is affecting energy and stamina, something a prescriber or dietitian can help balance. Under-eating on treatment is a real phenomenon, and fatigue presenting as breathlessness on exertion can follow from it.
Breathlessness is sometimes mentioned by people who are wondering whether they'd even qualify for treatment. At nume, every consultation is read by a GPhC-registered Independent Prescriber (not software) before any prescription is issued. Part of that review includes existing cardiovascular and respiratory conditions. Someone with poorly controlled heart failure or significant pulmonary disease would not receive a prescription without careful clinical consideration, precisely because weight-loss treatment in that context needs oversight.
The Wegovy treatment overview covers the licensed indications and eligibility criteria in detail. The cost of private prescribing (including what's included in a complete service) is set out on the Wegovy cost page for anyone weighing up the private route. A service worth trusting builds safety assessment into the process, not as a formality but as the clinical gate it is. That is worth checking before committing to any provider. It is also worth knowing that bad breath on semaglutide is among the unexpected symptoms some patients raise with their prescriber, and understanding the full picture of what to monitor helps you get more from those conversations.
If you have a specific concern about a symptom you've noticed, the right next step is a conversation with a prescriber rather than a page. Check your eligibility and start a free consultation, our prescribers can review your history and give you a considered answer, not a generic one.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.